Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Pregnancy outcomes in patients exposed to interferon beta-1b.
Synthetic Biologics Reports Results of Independent Third Party Evaluations of Trimesta™ Data from Investigator-Sponsored Phase 2 Clinical Trial for Relapsing-Remitting Multiple Sclerosis
Uhthoff's phenomena in MS-clinical features and pathophysiology.
IgE-Mediated Allergic Reactions after the First Administration of Glatiramer Acetate in Patients with Multiple Sclerosis.
Rituximab, an anti-CD20 monoclonal antibody: History & mechanism: Off label rituximab use in transplant patients
New approaches in the management of multiple sclerosis.
The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
Pharmacology and therapeutic potential of interferons.
Genzyme’s Lemtrada Approved by the FDA
Natalizumab treatment during pregnancy - effects on the neonatal immune system.
FDA approval letter for daclizumab for the prophylaxis of acute organ rejection in patients receiving renal transplants
[Results of a comparative clinical trial of the Russian Β - interferon-1b bioanalogue (infibeta)].
Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome.
Reviewing the Unmet Needs of Patients with Multiple Sclerosis.
The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.
More to come: humoral immune responses in MS.
Takeda Pharmaceutical: New Drug Application Approval in Japan for Copaxone® Subcutaneous Injection 20 mg Syringe, a Drug for the Treatment of Multiple Sclerosis
Federation of Clinical Immunology Societies 2012
Teva and Active Biotech remain committed to the development of NERVENTRA® (laquinimod) for multiple sclerosis following the negative opinion from the EMA's CHMP
Heterogeneity of serum gelatinases MMP-2 and MMP-9 isoforms and charge variants.
Santhera to discontinue sale of Catena® in Canada
First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models.
Sample-size calculations for short-term proof-of-concept studies of tissue protection and repair in multiple sclerosis lesions via conventional clinical imaging
Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders.
Neuropathology of white matter disease in Leber's hereditary optic neuropathy.

Pages